Publications by authors named "Michael Heider"

Claim this Profile
M
Molecular basis of SIFI activity in the integrated stress response.
Zhi Yang, Diane L Haakonsen, Michael Heider, Samuel R Witus, Alex Zelter

Nature· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine Response.
Krischan Braitsch, Samuel D Jeske, Jacob Stroh, Maike Hefter, Louise Platen, Michael Heider

Vaccines (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stress response silencing by an E3 ligase mutated in neurodegeneration.
Diane L Haakonsen, Michael Heider, Andrew J Ingersoll, Kayla Vodehnal, Samuel R Witus

Nature· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Model Requirements for Explainable AI: A Template and Exemplary Case Study.
Michael Heider, Helena Stegherr, Richard Nordsieck, Jörg Hähner

Artif Life· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Guus J J E Heynen, Francis Baumgartner, Michael Heider, Upayan Patra, Maximilian Holz

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma.
Carmen Paulmann, Ria Spallek, Oleksandra Karpiuk, Michael Heider, Isabell Schäffer

EMBO J· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Jacob Stroh, Anja Seckinger, Michael Heider, Martina Rudelius, Ruth Eichner

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial evaluation of [F]-FACBC for PET imaging of multiple myeloma.
Volker Morath, Michael Heider, Markus Mittelhäuser, Hannes Rolbieski, Jacob Stroh

EJNMMI Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Michael Heider, Katharina Nickel, Marion Högner, Florian Bassermann

Oncol Res Treat· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
Michael Heider, Sandra Grass, Veronika Dill, Stephanie Rämisch, Christof Winter

Transfus Apher Sci· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Michael Heider, Ruth Eichner, Jacob Stroh, Volker Morath, Anna Kuisl

Mol Cell· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.
Catharina Müller-Thomas, Michael Heider, Guido Piontek, Martin Schlensog, Florian Bassermann

Br J Haematol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Ruth Eichner, Michael Heider, Vanesa Fernández-Sáiz, Frauke van Bebber, Anne-Kathrin Garz

Nat Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis